asco lung cancer highlights, pt 11: nintedanib with second line chemotherapy
Published 10 years ago • 390 plays • Length 5:20Download video MP4
Download video MP3
Similar videos
-
5:40
asco lung cancer highlights, pt 12: ganetespib with second line chemotherapy
-
14:00
asco 2021 lung recap: impower010: atezolizumab after chemo in non-small cell lung cancer
-
6:38
asco lc highlights, pt 6: benefit of chemotherapy vs. egfr inhibitor therapy in second line
-
2:11
asco lung cancer highlights, pt 13: immune checkpoint inhibitor mpdl3280a in advanced nsclc
-
16:03
grace targeted therapies lung cancer 2021 -the role of chemotherapy in driver positive patients
-
7:39
chemotherapy and immunotherapy for patients with kras mutations - asco lung review 2022
-
5:27
asco 2021 lung recap: lurbinectedin in small cell lung cancer and the failed atlantis trial
-
7:19
discovery of ros1 inhibitor drugs in response to lorlatinib resistance by alexandria finkel
-
7:38
lung cancer ஆரம்ப அறிகுறிகள்... | தடுப்பது எப்படி..? | apollo porton | lung cancer | treatment
-
6:52
combination chemotherapy and immunotherapy for patients with high pd-l1 nsclc - 2022 program: lcvl
-
7:44
asco lung cancer highlights, part 1: introduction to stage iii nsclc
-
23:32
gracecast-077_lung-cancer_asco 2011 highlights - advanced/metastatic nsclc
-
6:57
lung cancer video library - chemo immuno therapy combinations in advanced nsclc
-
8:35
asco lung cancer roundtable - nsclc - the cityscape trial: anti tigit & immune checkpoint inhibitor
-
11:13
gracecast-091_lung-cancer_highlights 2011: the egfr axis
-
7:54
keytruda combined with anti-vegf treatment:use in patients with advanced nsclc-asco lung review 2022
-
8:45
asco lung cancer highlights, part 2: optimizing radiation for stage iii nsclc
-
1:47
alk rearrangements: what are they, and who has them?
-
3:40
platinum-based chemo doublets: backbone for nsclc treatment
-
6:40:28
full video ondemand -targeted therapies patient forum 2022 - for those living with lung cancer
-
8:13
checkmate 816: combining chemo and opdivo - asco lung review 2022
-
2:01
grace targeted therapies lung cancer 2021 - data learned from ensartinib for ros1 in clinical trial?